BioCentury | Apr 21, 2020
Product Development

FDA green-lights more than 70 COVID-19 trials via treatment acceleration program

...ViralClear Pharmaceuticals Inc., which last week submitted an application via CTAP for Vicromax merimepodib. The IMPDH...
...are expected within three months. According to BioCentury’s Resource Center , Vicromax is the only IMPDH...
...Further analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Targets IMPDH - Inosine monophosphate dehydrogenase Elizabeth...
BioCentury | Aug 11, 2017
Regulation

Foundation for inclusion

...hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). CellCept is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH...
BioCentury | Aug 1, 2016
Company News

Vertex, Trek Therapeutics deal

...undisclosed milestones and royalties. Lomibuvir, a non-nucleoside HCV NS5B polymerase inhibitor, and merimepodib, an inosine monophosphate dehydrogenase (IMPDH...
BioCentury | Jan 18, 2016
Clinical News

FF-10501: Preliminary Phase I/II data

...Tokyo:4901), Tokyo, Japan Product: FF-10501 , FF-10501-01 Business: Cancer Molecular target: Inosine monophosphate dehydrogenase (IMPDH) Description: Inosine monophosphate dehydrogenase (IMPDH...
BioCentury | Sep 2, 2013
Clinical News

CellCept mycophenolate mofetil regulatory update

...kidney, heart, liver, lung or pancreas transplants. In the US, the reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH...
BioCentury | Mar 4, 2013
Strategy

Simple solution

...mycophenolate mofetil as CellCept to prevent rejection in organ transplants. The reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH...
BioCentury | Oct 1, 2012
Clinical News

CellCept mycophenolate mofetil regulatory update

...renal transplants in combination with cyclosporine and corticosteroids. CellCept is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH...
BioCentury | Oct 1, 2012
Clinical News

Myfortic mycophenolic acid regulatory update

...renal transplants in combination with cyclosporine and corticosteroids. CellCept is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH...
BioCentury | Sep 27, 2012
Company News

FDA unveils REMS for mycophenolate drugs

...renal transplants in combination with cyclosporine and corticosteroids. CellCept is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH...
BioCentury | Jul 23, 2012
Clinical News

CellCept mycophenolate mofetil regulatory update

...co-administered with proton pump inhibitors in transplant patients. Roche markets the reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH...
Items per page:
1 - 10 of 139